- Home
- LFS vs ELTX Comparison
LFS vs ELTX Comparison
Compare LFS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFS | ELTX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | Japan | United States |
| Employees | N/A | 26 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.3M | 144.5M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | LFS | ELTX |
|---|---|---|
| Price | $4.05 | $8.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 2.6M | 111.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.16 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $76,556,507.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.06 | ★ N/A |
| Revenue Growth | ★ 12.13 | N/A |
| 52 Week Low | $1.58 | $4.60 |
| 52 Week High | $12.49 | $12.62 |
Technical Indicators
Market Signals| Indicator | LFS | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.30 |
| Support Level | N/A | $7.90 |
| Resistance Level | N/A | $9.00 |
| Average True Range (ATR) | 0.00 | 0.62 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 36.32 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.